Robert Figlin, MD
Enriched profileInterim Director, Cedars-Sinai Cancer; Deputy Director, Samuel Oschin Comprehensive Cancer Institute; Steven Spielberg Family Chair in Hematology-Oncology; Professor of Medicine and Biomedical Sciences · Cedars-Sinai Medical Center
Robert Figlin is Interim Director, Cedars-Sinai Cancer; Deputy Director, Samuel Oschin Comprehensive Cancer Institute; Steven Spielberg Family Chair in Hematology-Oncology; Professor of Medicine and Biomedical Sciences at Cedars-Sinai Medical Center. ClinicalTrials.gov lists 8 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 2 Sept 2026
Robert Figlin, MD, is Interim Director, Cedars-Sinai Cancer at Cedars-Sinai Medical Center (Cedars-Sinai Cancer). The public record shows 716 publications with 52,794 citations (h-index 107), centered on Kidney Cancer / RCC, Lung Cancer (NSCLC/SCLC), Kidney Neoplasms. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 11 companies, 6 NIH-funded awards (1993–2013).
- Top research focus: Kidney Cancer / RCC
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 2 Sept 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 2 Sept 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Sponsor: Jonsson Comprehensive Cancer Center
- Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Sponsor: Jonsson Comprehensive Cancer Center
Industry payments
Updated 2 Sept 2026
11 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:
- 4DMedical USA IncProgram year202413 payments$62,397openpaymentsdata.cms.gov ↗
- Kyowa Kirin, Inc.Program year20243 payments
- Iovance Biotherapeutics, Inc.Program year20241 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor83.1%Lenvima41%Cabometyx33%Everolimus26%Part D<11 patientsHypoxia-inducible Factor Inhibitor16.9%Welireg100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 2 Sept 2026
6 NIH research awards on record, funded 1993–2013 per NIH RePORTER. The latest:
Publications
None on file yet. We only list publications we can confidently match to this person. Why? →
Online presence
Updated 2 Sept 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/robert-figlin-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/robert-figlin-3b1072148
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Robert-Figlin
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- X / Twitter
x.com/ASCO/status/1944849562931282216
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗ - X / Twitter
x.com/cedarssinai/status/475019383849627648
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 2 Sept 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Medical College of Pennsylvania (1976); internal medicine residency and chief residency, Cedars-Sinai Medical Center; hematology-oncology fellowship, UCLA David Geffen School of Medicine
1976provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cedars-sinai.org ↗
Editorial & leadership roles
journal and society appointments- Honorary Editor
Kidney Cancer Journal
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →kidney-cancer-journal.com ↗ - Fellow
American College of Physicians (FACP)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →accc-cancer.org ↗
Secondary affiliations
appointments beyond the home institution- Emeritus Professor of Medicine and Urology
David Geffen School of Medicine at UCLA
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →accc-cancer.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medscape.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Beth Karlan, MD
Cedars-Sinai Medical Center
Raj Makkar, MD
Cedars-Sinai Medical Center
Paul Noble, MD
Cedars-Sinai Medical Center
Stephen Freedland, MD
Cedars-Sinai Medical Center